| Authors: |
Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yuca E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Scott SS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Paez Arango N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cruz Pico CX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Saridogan T; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shariati M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Class CA; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bristow CA; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vellano CP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zheng X; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gonzalez-Angulo AM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Su X; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tapia C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chen K; The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Francesco MED; Institute for Applied Cancer Science, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Draetta GF; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jones P; Institute for Applied Cancer Science, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heffernan TP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Marszalek JR; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. fmeric@mdanderson.org. |
